Melanoma Research最新文献_第2页

Total body skin examination visits by dermatology providers in the 2011-2016 National Ambulatory Medical Care Survey. 2011-2016 年全国流动医疗护理调查中皮肤科医疗服务提供者的全身皮肤检查访问量。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-12-01 Epub Date: 2024-10-30 DOI: 10.1097/CMR.0000000000000995

Brandon Smith, Joe K Tung, Annie I Chen, Cassandra Mohr, Malgorzata K Nowakowska, Mackenzie R Wehner, Laura K Ferris

引用次数: 0

Synchronous double primary vulvar melanoma: a not so rare possibility. A clinical and dermoscopic case study. 同步双原发性外阴黑色素瘤：一种并不罕见的可能性。临床和皮肤镜病例研究。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-12-01 Epub Date: 2024-06-24 DOI: 10.1097/CMR.0000000000000989

Vincenzo De Giorgi, Giovanni Cecchi, Gabriella Perillo, Biancamaria Zuccaro, Piero Covarelli

{"title":"Synchronous double primary vulvar melanoma: a not so rare possibility. A clinical and dermoscopic case study.","authors":"Vincenzo De Giorgi, Giovanni Cecchi, Gabriella Perillo, Biancamaria Zuccaro, Piero Covarelli","doi":"10.1097/CMR.0000000000000989","DOIUrl":"10.1097/CMR.0000000000000989","url":null,"abstract":"Vulvar melanoma is considered rare, but it is the second most frequent vulvar neoplasm; 2% of melanomas in women arise in the vulvar area. It is important to highlight how the characteristics of vulvar melanoma differentiate it from classic cutaneous melanoma. Vulvar melanoma has different risk factors and clinical and dermoscopic characteristics; moreover, it has a higher recurrence rate and a greater likelihood of multifocality. Here, we present a case of a 44-year-old patient with two primary vulvar melanomas located on opposite sides of her vulva. The lesions were both flat, but they had distinct clinical and dermoscopic appearances. Melanoma of the genital tract is likely the result of a multifocal disorder of the melanocytes within the mucosa that inhabit the perineal squamous epithelium. The risk factors of vulvar melanoma differ from those of classical cutaneous melanomas. Vulvar melanoma occurs in an area shielded from ultraviolet radiation; the primary risk factors include chronic inflammatory disease, genetic susceptibility, irritant agents and viral infections. This case study reveals how a close examination of the genital area is important and how dermoscopy can aid in the differential diagnosis of vulvar lesions. Inspections of the genital area should be particularly thorough if a melanoma is detected there, given the higher risk of multifocality in that part of the body.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"540-543"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pediatric melanoma incidence and survival: a fifteen-year nationwide retrospective cohort study in Korea. 小儿黑色素瘤的发病率和存活率：韩国一项为期十五年的全国性回顾性队列研究（2004-2019 年）。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-12-01 Epub Date: 2024-08-30 DOI: 10.1097/CMR.0000000000001000

Isaac Kim, Jisu Oh, Siyeoung Yoon, Man-Yong Han, Jaiwoo Chung, Younghoon Jung, Hyun-Il Lee, Soonchul Lee

{"title":"Pediatric melanoma incidence and survival: a fifteen-year nationwide retrospective cohort study in Korea.","authors":"Isaac Kim, Jisu Oh, Siyeoung Yoon, Man-Yong Han, Jaiwoo Chung, Younghoon Jung, Hyun-Il Lee, Soonchul Lee","doi":"10.1097/CMR.0000000000001000","DOIUrl":"10.1097/CMR.0000000000001000","url":null,"abstract":"The aim of this study was to explore the epidemiology of cutaneous malignant melanoma (CMM) and the associated risk factors influencing its occurrence and survival among Koreans aged <20 years. In this retrospective cohort investigation, we identified cases of incident melanoma diagnosed in Korean patients aged 0-19 years between 2004 and 2019, utilizing the National Health Insurance database. We assessed annual fluctuations in age-adjusted incidence rates and examined 5-year survival rates based on various factors, including sex, age, income level, sun-exposed sites, and the Charlson Comorbidity Index. Of 1160 patients, 51.4% were male and 48.6% were female. The mean age of the patients was 11 years, mostly belonging to the top 25% high-income group. The head and neck regions were the most frequently affected sites. The overall age-adjusted incidence rate of melanoma was 0.22 per 100,000 persons. This rate witnessed a decline of 4.5% annually from 2004 to 2012, followed by a subsequent increase of 12.6% annually from 2012 to 2019. Notably, patients with CMM in low-sun-exposed sites exhibited poorer survival rates compared with those in high-sun-exposed areas ( P < 0.05). The incidence of melanomas in children and adolescents in Korea has shown a rising trend since 2012. Further research is needed to investigate the etiology and risk factors in pediatric patients.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"528-534"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142109347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting. 在三甲医院接受治疗的老年黑色素瘤患者接受靶向治疗的疗效和毒性的真实证据。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-12-01 Epub Date: 2024-08-30 DOI: 10.1097/CMR.0000000000000997

Ronen Stoff, Svetomir N Markovic, Robert R McWilliams, Lisa A Kottschade, Heather N Montane, Anastasios Dimou, Arkadiusz Z Dudek, Winston Tan, Roxana S Dronca, Mahesh Seetharam, Ruqin Chen, Matthew S Block

{"title":"Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting.","authors":"Ronen Stoff, Svetomir N Markovic, Robert R McWilliams, Lisa A Kottschade, Heather N Montane, Anastasios Dimou, Arkadiusz Z Dudek, Winston Tan, Roxana S Dronca, Mahesh Seetharam, Ruqin Chen, Matthew S Block","doi":"10.1097/CMR.0000000000000997","DOIUrl":"10.1097/CMR.0000000000000997","url":null,"abstract":"Melanoma is the deadliest form of skin cancer. The median age at diagnosis is 66. While most patients are treated with immunotherapy, the use of targeted therapy is a valid alternative for patients whose tumors harbor a BRAF or c-KIT driver mutation. These agents, while effective, come with a variety of side effects which limit their use, especially in older patients. We sought to assess the efficacy and toxicity of these agents in older melanoma patients. Melanoma patients over 65 treated with BRAF/MEK or c-KIT inhibitors were retrospectively identified, and their data were analyzed for treatment efficacy and toxicity. All data were compared using the Chi-square test for categorical comparisons and the Kruskal-Wallis method for median comparisons. One hundred and sixteen patients were identified. One hundred and six patients were treated with BRAF/MEK inhibitors. The assessed response rate (RR) was 83% and was comparable across different subgroups, including advanced line patients and those with a more aggressive disease. The median progression free survival (PFS) was 7.9 months, and the median overall survival (OS) was 15.7 months. Twenty-seven percent experienced grade 3-4 toxicity leading to a 24% treatment discontinuation rate. Another 10 patients were treated with the c-KIT inhibitor imatinib, for whom the assessed RR was 55%. The median PFS was 4.3 months, and the median OS was 22.6 months. Forty percent needed dose reductions, yet none had to stop treatment due to adverse effects. The use of targeted therapy in older patients is effective yet challenging due to toxicity. Deploying mitigation strategies can help maximizing their usefulness.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"510-518"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142109348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term outcomes and patterns of recurrence in patients with thin melanoma and a negative sentinel lymph node biopsy: a single-center experience. 薄型黑色素瘤前哨淋巴结活检阴性患者的长期疗效和复发模式：单中心经验。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-12-01 Epub Date: 2024-06-14 DOI: 10.1097/CMR.0000000000000986

Maayan Shemer, Michal Shimonovitz, Rozalin Furer, Adam Abu-Abeid, Danit Dayan, Schlomo Schneebaum, Mor Miodovnik, Eran Nizri

{"title":"Long-term outcomes and patterns of recurrence in patients with thin melanoma and a negative sentinel lymph node biopsy: a single-center experience.","authors":"Maayan Shemer, Michal Shimonovitz, Rozalin Furer, Adam Abu-Abeid, Danit Dayan, Schlomo Schneebaum, Mor Miodovnik, Eran Nizri","doi":"10.1097/CMR.0000000000000986","DOIUrl":"10.1097/CMR.0000000000000986","url":null,"abstract":"The majority of patients diagnosed with melanoma have thin melanomas (≤1 mm). Data on the rate and pattern of recurrence after a negative sentinel lymph node biopsy (SLNB) are sparse. We retrospectively searched our institutional database and retrieved the records of patients with thin melanomas who underwent an SLNB with negative results. We analyzed patterns of recurrence, time to recurrence, and mode of diagnosis. Thirteen of the 198 patients with thin melanomas and negative SLNB results had tumor recurrence (6.5%): two local in transit (15.4%), three regional (21.3%), and eight distant (61.5%). Distant recurrences tended to occur later than local or regional ones [median disease-free survival = 50 months (95% confidence interval: 36.1-63.9) vs. 34 and 15 months (95% confidence interval: 5.4-24.6), P = 0.005, respectively]. The percentage of patients with tumor thickness ≥0.8 mm was higher among those who sustained recurrence (84.6 vs. 64.9% for no recurrence, P = 0.04). The majority of patients with recurrence were not being followed up when diagnosed (69%), and they are presented because of clinical symptoms. Patients with recurrence had lower survival compared with those without recurrence (median: 118 months vs. ongoing survival, P < 0.001, respectively). Melanoma recurrence in patients with thin melanomas and negative SLNBs is rare, tends to be distant, and negatively affects prognosis. Recurrence tends to occur in patients with melanoma thickness ≥0.8 mm. Further studies are needed to identify patients with high recurrence risk and determine optimal follow-up protocols.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"535-539"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transcutaneous sentinel lymph node detection in skin melanoma with near-infrared fluorescence imaging using indocyanine green. 利用吲哚菁绿的近红外荧光成像技术经皮检测皮肤黑色素瘤的前哨淋巴结。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-12-01 Epub Date: 2024-08-02 DOI: 10.1097/CMR.0000000000000994

Bo E Zweedijk, Antonius W Schurink, Thijs van Dalen, Tessa M van Ginhoven, Cornelis Verhoef, Bernd Kremer, Denise E Hilling, Stijn Keereweer, Dirk J Grünhagen

{"title":"Transcutaneous sentinel lymph node detection in skin melanoma with near-infrared fluorescence imaging using indocyanine green.","authors":"Bo E Zweedijk, Antonius W Schurink, Thijs van Dalen, Tessa M van Ginhoven, Cornelis Verhoef, Bernd Kremer, Denise E Hilling, Stijn Keereweer, Dirk J Grünhagen","doi":"10.1097/CMR.0000000000000994","DOIUrl":"10.1097/CMR.0000000000000994","url":null,"abstract":"The aim of the study is to assess whether indocyanine green (ICG) fluorescence can replace technetium in the preoperative detection of sentinel lymph nodes (SLN) from cutaneous melanoma. The current golden standard for SLN detection is the radioisotope technetium. A promising alternative is fluorescence imaging (FLI) using ICG. In this study, we enrolled patients undergoing sentinel lymph node biopsy (SLNB) for skin melanoma at the Erasmus Medical Center between November 2022 and July 2023. The SLNB procedure was performed as a standard of care. After general anesthesia, ICG was injected intradermally around the primary tumor site. Both the patient and the surgeon were not blinded for the location of the SLN. FLI was performed before incision, in vivo after incision, and ex vivo. Fluorescent SLNs were confirmed using the gamma probe in all cases. Thirty-two patients were included in this study, and a total of 39 SLNs were harvested. The transcutaneous detection rate of ICG was 21.9%. The combined ex vivo ICG fluorescence and technetium uptake was 94.9%. One SLN contained only ICG (2.6%) and one SLN contained only technetium-uptake (2.6%). FLI using ICG resulted in a relatively low transcutaneous detection, which means that exclusive use of this technique in its present form is not feasible. However, we did find a high accumulation of ICG in the SLN, indicating the potential of ICG in combination with other imaging techniques.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"504-509"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141860205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of wide local excision of a primary lesion in cutaneous malignant melanoma: a retrospective analysis of its usefulness in local and general control of disease. 对皮肤恶性黑色素瘤原发病灶进行大范围局部切除的作用：对其在局部和总体控制疾病方面作用的回顾性分析。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-12-01 Epub Date: 2024-09-25 DOI: 10.1097/CMR.0000000000000999

Eleonora Nacchiero, Massimo Giotta, Fabio Robusto, Maria Elvira Metta, Valentina Ronghi, Rossella Elia, Paolo Trerotoli, Michele Maruccia, Giuseppe Giudice

{"title":"The role of wide local excision of a primary lesion in cutaneous malignant melanoma: a retrospective analysis of its usefulness in local and general control of disease.","authors":"Eleonora Nacchiero, Massimo Giotta, Fabio Robusto, Maria Elvira Metta, Valentina Ronghi, Rossella Elia, Paolo Trerotoli, Michele Maruccia, Giuseppe Giudice","doi":"10.1097/CMR.0000000000000999","DOIUrl":"10.1097/CMR.0000000000000999","url":null,"abstract":"Currently, wide local excision is recommended after the primary excision of cutaneous melanomas. The definition of margins for wide local excision indicated by the guidelines has remained unchanged over the years, although the reported indications are derived from fairly dated studies in which melanomas tended to be thicker or in advanced stages at diagnosis. This study aimed to retrospectively evaluate the usefulness of wide local excision for local and general control of the disease and to identify patients who had benefited from the wide local excision procedure in terms of prognosis improvement. This retrospective observational study was conducted on patients who had undergone surgery for melanoma at a single institution. The primary endpoint was progression-free survival after wide local excision in patients with or without residual melanoma. The secondary endpoint was to evaluate which patients' demographic features and melanoma histological data were associated with residual melanoma after wide local excision. In the univariate model, melanoma-positive wide local excision resulted in the worst progression-free survival; however, this association was not confirmed in the multivariate model. The results also showed that Breslow thickness was the only factor associated with an increased risk of metastasis to the wide local excision area. According to the receiver operating characteristic analysis, the optimum cutoff value of Breslow's thickness to predict a tumor-positive wide local excision was 2.31 mm for males and 2.4 mm for females.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"519-527"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of statins on melanoma survival: a systematic review and meta-analysis. 他汀类药物对黑色素瘤存活率的影响：系统回顾和荟萃分析。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-12-01 Epub Date: 2024-09-12 DOI: 10.1097/CMR.0000000000001001

Tyler McKechnie, Gaurav Talwar, Shan Grewal, Austine Wang, Cagla Eskicioglu, Elena Parvez

{"title":"The impact of statins on melanoma survival: a systematic review and meta-analysis.","authors":"Tyler McKechnie, Gaurav Talwar, Shan Grewal, Austine Wang, Cagla Eskicioglu, Elena Parvez","doi":"10.1097/CMR.0000000000001001","DOIUrl":"10.1097/CMR.0000000000001001","url":null,"abstract":"Statin use may decrease recurrence and improve survival in patients with melanoma. In this systematic review and meta-analysis, we examine the current body of literature concerning the use of statins as an adjunctive therapy in melanoma, Medline, EMBASE, CENTRAL, and PubMed were systematically searched from inception through to April 2023. Studies were included if they compared patients with melanoma receiving and not receiving statin therapy concurrently with their oncologic treatment in terms of long-term oncologic outcomes. The primary outcome was 5-year overall survival (OS). Meta-analyses was performed with DerSimonian and Laird random effects. Risk of bias was assessed with the ROBINS-I and GRADE was used to assess certainty of evidence. From 952 citations, eight non-randomized studies were identified. Included studies were conducted between 2007 and 2022. Random effects meta-analysis of adjusted hazard ratios from three studies suggested an improvement in 5-year OS with statin use with wide 95% confidence intervals (CIs) crossing the line of no effect (hazard ratio 0.87, 95% CI: 0.73-1.04, P = 0.12, I2 = 95%, very-low certainty). Outcome reporting was heterogeneous across all other oncologic outcomes such that pooling of data was not possible. Risk of bias was serious for seven studies and moderate for one study. This systematic review of studies evaluating the impact of statin use on survival in patients with melanoma found a 13% reduction in risk of death at 5 years from diagnosis - a point estimate suggesting benefit. However, the wide 95% CIs and resultant type II error risk create significant uncertainty.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"475-486"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142291184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ATF3 regulates CDC42 transcription and influences cytoskeleton remodeling, thus inhibiting the proliferation, migration and invasion of malignant skin melanoma cells. ATF3 可调节 CDC42 的转录并影响细胞骨架的重塑，从而抑制恶性皮肤黑色素瘤细胞的增殖、迁移和侵袭。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-11-26 DOI: 10.1097/CMR.0000000000001011

Liang Niu, Shuo Liu, Jiuxiao Shen, Jin Chang, Xiaojing Li, Ling Zhang

{"title":"ATF3 regulates CDC42 transcription and influences cytoskeleton remodeling, thus inhibiting the proliferation, migration and invasion of malignant skin melanoma cells.","authors":"Liang Niu, Shuo Liu, Jiuxiao Shen, Jin Chang, Xiaojing Li, Ling Zhang","doi":"10.1097/CMR.0000000000001011","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001011","url":null,"abstract":"Cutaneous malignant melanoma (CMM) is one of the most aggressive and lethal types of skin cancer. Cytoskeletal remodeling is a key factor in the progression of CMM. Previous research has shown that activating transcription factor 3 (ATF3) inhibits metastasis in bladder cancer by regulating actin cytoskeleton remodeling through gelsolin. However, whether ATF3 plays a similar role in cytoskeletal remodeling in CMM cells remains unknown. Various gene and protein expression analyses were performed using techniques such as reverse transcription quantitative PCR, western blot, immunofluorescent staining, and immunohistochemical staining. CMM viability, migration, and invasion were examined through cell counting kit-8 and transwell assays. The interactions between cell division cycle 42 (CDC42) and ATF3 were investigated using chromatin immunoprecipitation and dual-luciferase reporter assays. CDC42 was upregulated in CMM tissues and cells. Cytoskeletal remodeling of CMM cells, as well as CMM cell proliferation, migration, and invasion, were inhibited by CDC42 or ATF3. ATF3 targeted the CDC42 promoter region to regulate its transcriptional activity. ATF3 suppresses cytoskeletal remodeling in CMM cells, thereby inhibiting CMM progression and metastasis through CDC42. This research may provide a foundation for using ATF3 as a therapeutic target for CMM.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142730347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort. 晚期黑色素瘤进展后继续使用免疫检查点抑制剂对总生存期的实际效果：来自 Melbase 队列的估计。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-11-11 DOI: 10.1097/CMR.0000000000000973

Camille Macaire, Wendy Lefevre, Sophie Dalac, Henri Montaudié, Delphine Legoupil, Olivier Dereure, Caroline Dutriaux, Marie Thérèse Leccia, François Aubin, Jean Jacques Grob, Philippe Saiag, Julie De Quatrebarbes, Eve Maubec, Thierry Lesimple, Florence Granel-Brocard, Laurent Mortier, Stéphane Dalle, Céleste Lebbé, Chloé Prod'homme

{"title":"Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort.","authors":"Camille Macaire, Wendy Lefevre, Sophie Dalac, Henri Montaudié, Delphine Legoupil, Olivier Dereure, Caroline Dutriaux, Marie Thérèse Leccia, François Aubin, Jean Jacques Grob, Philippe Saiag, Julie De Quatrebarbes, Eve Maubec, Thierry Lesimple, Florence Granel-Brocard, Laurent Mortier, Stéphane Dalle, Céleste Lebbé, Chloé Prod'homme","doi":"10.1097/CMR.0000000000000973","DOIUrl":"https://doi.org/10.1097/CMR.0000000000000973","url":null,"abstract":"The link between palliative care and oncology must continue to develop, taking into account advances in treatment.Immune checkpoint inhibition (ICI) for metastatic melanoma is associated with different types of response, making it difficult to assess the benefits to the patient. Some clinical trials suggest a survival advantage of ICI even in the absence of an objective radiographic response. The aim of this study is to assess the impact of continuing ICI after progression of the disease on the overall survival (OS) in a cohort of final-line metastatic melanoma patients. Clinical data from 120 patients with metastatic melanoma were collected via Melbase, a French multicentric biobank, prospectively enrolling unresectable melanoma. Two groups were defined: patients continuing final-line ICI at progression (treated) and patients stopping ICI at progression (controls). The primary end-point is the OS from progression. Propensity score weighting was used to correct for indication bias. From the 120 patients, 72 (60%) continued ICI. Median OS from progression was 4.2 months [95% confidence interval (CI) 2.6-6.27] in the treated group and median OS was 1.3 months (95% CI 0.95-1.74) in the control group (P < 0.0001). The calculated hazard ratio was 0.20 (0.13-0.33). Continued ICI was discovered to have an association with a higher rate of hospitalization at the end of life; more treatments received in the last 15 days of life and less utilization of specialist palliative care. This study discovered that patients with metastatic melanoma show a significant decrease in the instantaneous probability of mortality when they continue with finale-line ICI after progression.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0